1 |
许俊来.塞来昔布联合甲氨蝶呤治疗类风湿关节炎患者的临床效果[J].临床合理用药杂志,2022,15(9):125-127.
|
|
XU J L. Clinical effect of celecoxib combined with methotrexate on patients with rheumatoid arthritis[J]. Chin. J. Clin. Ration. Drug Use, 2022, 15(9): 125-127.
|
2 |
ZHANG L, LI M, WANG W, et al.. Celecoxib alleviates denervation-induced muscle atrophy by suppressing inflammation and oxidative stress and improving microcirculation[J/OL]. Biochem. Pharmacol., 2022, 203: 115186[2023-11-07]. .
|
3 |
KRASSELT M, BAERWALD C. Celecoxib for the treatment of musculoskletal arthritis[J]. Expert Opin. Pharmacother., 2019,18: 1-14.
|
4 |
KISHORE N, RAJA M D, KUMAR C S, et al.. Lipid carriers for deliverof celecoxib: in vitro, in vivo assessment of nanomedicine in rheumatoid arthritis[J]. Eur. J. Lipid Sci. Technol., 2015, 118(6): 949-958.
|
5 |
冯蕊,陈冠军,刘莉,等.LC-MS法测定塞来昔布中2个苯肼类基因毒性杂质[J].中国新药杂志,2021,30(2):182-186.
|
|
FENG R, CHEN G J, LIU L, et al.. Determination of two phenylhydrazine-like genotoxic impurities in celecoxib by LC-MS[J]. Chin. J. N. Drugs, 2021, 30(2): 182-186.
|
6 |
KAUSAR N, ULLAH S, KHAN M A, et al.. Celebrex derivatives: synthesis, α-glucosidase inhibition, crystal structures and molecular docking studies[J/OL]. Bioorg. Chem., 2021, 106: 104499[2023-11-07]. .
|
7 |
CHOI J S, LEE D H, AHN J B, et al.. Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis[J/OL]. Mater. Sci. Eng. C Mater. Biol. Appl., 2020, 114: 111042[2023-11-07]. .
|
8 |
NOZOHOURI S, SHAYANFAR A, CÁRDENAS Z J, et al.. Solubility of celecoxib in N-methyl-2-pyrrolidone+water mixtures at various temperatures: experimental data and thermodynamic analysis[J]. Korean J. Chem. Eng., 2017, 34(5): 1435-1443.
|
9 |
孔凯丽.米诺膦酸原料药中基因毒性杂质的分析[J].山东化工,2022,51(10):100-103.
|
|
KONG K L. Analysis of genotoxic impurity in minodronic acid API[J]. Shandong Chem. Ind., 2022, 51(10): 100-103.
|
10 |
KALAUZ A, KAPUI I. Determination of potentially genotoxic impurities in crotamiton active pharmaceutical ingredient by gas chromatography[J/OL]. J. Pharm. Biomed. Anal., 2022, 210: 114544[2023-11-07]. .
|
11 |
葛雨琦,叶晓霞,乐健,等.N-亚硝胺类基因毒性杂质毒性与检测方法研究进展[J].药物分析杂志,2020,40(1):83-89.
|
|
GE Y Q, YE X X, LE J, et al.. Research progress on toxicity and detection methods of N-nitrosamines genotoxic impurities[J]. Chin. J. Pharm. Anal., 2020, 40(1): 83-89.
|
12 |
杨竹,杭太俊,郭晓迪,等.N-亚硝胺类基因毒性杂质的研究进展[J].药学与临床研究,2020,28(4):270-274.
|
|
YANG Z, HANG T J, GUO X D, et al.. A review of research progress on N-nitrosamine genotoxic impurities[J]. Pharm. Clin. Res., 2020, 28(4): 270-274.
|
13 |
FU X, WANG X, XIA Z, et al.. Preparation of dummy molecularly imprinted polymers for selective extraction of aromatic amine genotoxic impurities[J/OL]. J. Chromatogr. A, 2022, 1685: 463617[2023-11-07]. .
|
14 |
LI S, DONG L, TANG K, et al.. Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS[J/OL]. J. Pharm. Biomed. Anal., 2022, 212: 114630[2023-11-07]. .
|
15 |
韩佳芮,徐艳梅,郝丽娟,等.药物中磺酸酯类基因毒性杂质测定方法研究进展[J].化学分析计量,2023,32(6):104-108.
|
|
HAN J R, XU Y M, HAO L J, et al.. Research progress in the determination of genotoxic impurities of sulfonates[J]. Chem. Anal. Meterage, 2023, 32(6): 104-108.
|
16 |
盛蕖,张涵,万悦,等.固相萃取与气相色谱⁃质谱法联用测定食用植物油和含脂肪食品中氯丙醇酯的方法验证研究[J].生物技术进展,2023,13(1):22-29.
|
|
SHENG Q, ZHANG H, WAN Y, et al.. Method validation research for the determination of chloropropanol esters in edible vegetable oil and fatty food by solid-phase extraction and gas chromatography-mass spectrometry[J]. Curr. Biotechnol., 2023, 13(1): 22-29.
|
17 |
鲁晶晶,冯芳.磺酸酯类基因毒性杂质研究进展[J].广州化工,2019,47(9):20-22.
|
|
LU J J, FENG F. Research progress on genotoxic impurities of sulfonate esters in medicines[J]. Guangzhou Chem. Ind., 2019, 47(9): 20-22.
|
18 |
于瑞董,俞海荣,杨杰,等.药物中基因毒性杂质磺酸酯类分析方法的研究近况[J].海峡药学,2019,31(8):122-125.
|
|
YU R D, YU H R, YANG J, et al.. Advances in studies on analytical techniques for sulfonate esters in pharmaceuticals[J]. Strait Pharm. J., 2019, 31(8): 122-125.
|
19 |
European Pharmacopoeia Commission. European Pharmacopoeia[M] 9th ed. Strasbourg: Council of Europe, 2017.
|
20 |
ICH M7(R1). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk[EB/OL]. [2023-11-07] .
|
21 |
NAKKA S, MUCHAKAYALA S K, MANABOLU SURYA S B. A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design[J/OL]. Results Chem, 2023, 6: 101019[2023-11-07]. .
|
22 |
MULLANGI S, RAVINDHRANATH K, YARALA M R, et al.. A sensitive LC-MS/MS method for the determination of potential genotoxic impurities in cinnarizine[J]. Ann. Pharm. Fr., 2023, 81(1): 74-82.
|